Fig. S10.

CD47 antagonism does not synergize with anti–PD-L1 checkpoint blockade therapy against syngeneic CT26 tumors. Survival of BALB/c mice bearing s.c. CT26 tumors treated with control nanobody, anti-CD47 nanobody A4, and/or anti–PD-L1 blocking antibody (10F.9G4). Mice were challenged with 5 × 10⁵ CT26 cells by s.c. injection and treated with i.p. injections of control nanobody (200 μg daily), A4 (200 μg daily), anti–PD-L1 (250 μg every other day), or the combination of A4 and anti–PD-L1 starting on day 0 post-tumor challenge for 14 d. The data shown are the mean (n = 10 per group) ± SEM.